Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PASG

PASG - Passage Bio Inc Stock Price, Fair Value and News

$7.45-0.65 (-8.02%)
Market Closed

Price Targets

PASG Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PASG Price Action

Last 7 days

-11.3%

Last 30 days

-14.9%

Last 90 days

-24.0%

Trailing 12 Months

-5.0%

PASG RSI Chart

PASG Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PASG Valuation

Market Cap

23.9M

Price/Earnings (Trailing)

-0.52

Price/Sales (Trailing)

11.45

Price/Free Cashflow

-0.76

PASG Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

PASG Fundamentals

PASG Revenue

Revenue (TTM)

2.3M

PASG Earnings

Earnings (TTM)

-45.5M

Earnings Growth (Yr)

-2.03%

Earnings Growth (Qtr)

-67.54%

PASG Profitability

Return on Equity

-242.72%

Return on Assets

-73.09%

Free Cashflow Yield

-131.85%

PASG Investor Care

Shares Dilution (1Y)

3.23%

Diluted EPS (TTM)

-14.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20220985.0K1.6M2.3M
2021000343.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Passage Bio Inc

PASG
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
 CEO
 WEBSITEpassagebio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES85

Passage Bio Inc Frequently Asked Questions

PASG is the stock ticker symbol of Passage Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Passage Bio Inc is 23.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, PASG's PE ratio (Price to Earnings) is -0.52 and Price to Sales (PS) ratio is 11.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PASG PE ratio will change depending on the future growth rate expectations of investors.